Lower dose of Neurocrine's movement disorder drug fails in study
(Reuters) - Neurocrine Biosciences Inc said a lower dose of its experimental drug to treat a rare movement disorder did not meet the main goal of a mi...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/_aINMiSjuA8/story01.htm
No comments:
Post a Comment